Comparison of Efficacy of Continuous Erythropoietin Receptor Activator ( CERA ) in Chronic Kidney Disease Patients versus Patients on Hemodialysis : Single Center Experience

2015 ◽  
Vol 61 ◽  
pp. 514-521
Author(s):  
Ayman Aly Seddik
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Erythropoietin Receptor ◽  
Single Center ◽  
Single Center Experience ◽  
Receptor Activator ◽  
Continuous Erythropoietin Receptor Activator

Influence of continuous erythropoietin receptor activator on markers of cardiovascular risk in chronic kidney disease patients

2013 ◽  
Vol 167 (6) ◽  
pp. 3070-3072 ◽  
Author(s):  
Annalisa Noce ◽  
Mariarita Dessì ◽  
Olga Durante ◽  
Simone Manca di Villahermosa ◽  
Maria Paola Canale ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Cardiovascular Risk ◽  
Kidney Disease ◽  
Erythropoietin Receptor ◽  
Receptor Activator ◽  
Continuous Erythropoietin Receptor Activator

scholarly journals Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease

2016 ◽  
Vol 2016 ◽  
pp. 1-9
Author(s):  
Piotr Bartnicki ◽  
Jacek Rysz ◽  
Beata Franczyk ◽  
Zbigniew Baj ◽  
Ewa Majewska
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Endothelial Dysfunction ◽  
Kidney Disease ◽  
Left Ventricle ◽  
Structure And Function ◽  
Erythropoietin Receptor ◽  
Receptor Activator ◽  
Continuous Erythropoietin Receptor Activator ◽  
And Function

Background. Cardiovascular morbidity and mortality are very high in patients with chronic kidney disease (CKD). The purpose of this study is to evaluate the impact of continuous erythropoietin receptor activator (CERA) on selected biomarkers of cardiovascular disease, left ventricle structure, and function in CKD.Material and Methods. Peripheral blood was collected from 25 CKD patients before and after CERA treatment and 20 healthy subjects. In serum samples, we assessed inflammatory markers (IL-1β, TNF-RI, TNF-RII, sFas, sFasL, MMP-9, TIMP-1, and TGF-β1), endothelial dysfunction markers (sE-selectin, sICAM-1, and sVCAM-1), and volume-related marker (NT-proBNP). All subjects underwent echocardiography and were evaluated for selected biochemical parameters (Hb, creatinine, and CRP).Results. Evaluated biomarkers and echocardiographic parameters of left ventricle structure were significantly increased but left ventricle EF was significantly decreased in CKD patients compared to controls. After CERA treatment, we observed a significant increase of Hb and left ventricle EF and a significant decrease of NT-proBNP and MMP-9. There was a significant negative correlation between Hb and TNF-RI, sICAM-1, and IL-1β.Conclusions. Our results indicate that selected biomarkers related to cardiovascular risk are significantly increased in CKD patients compared to controls. CERA treatment has anti-inflammatory action, diminishes endothelial dysfunction, and improves left ventricle function in these patients.

Sign in / Sign up

Export Citation Format

Share Document